203 related articles for article (PubMed ID: 32158623)
1. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
Nie W; Qian J; Xu MD; Gu K; Qian FF; Hu MJ; Lu J; Gan L; Zhang XY; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
Oncoimmunology; 2020; 9(1):1731072. PubMed ID: 32158623
[TBL] [Abstract][Full Text] [Related]
2. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
3. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.
Liu M; Xia S; Zhang X; Zhang B; Yan L; Yang M; Ren Y; Guo H; Zhao J
Lung Cancer; 2022 Aug; 170():148-155. PubMed ID: 35792434
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
Nie W; Qian J; Xu MD; Gu K; Qian FF; Lu J; Zhang XY; Wang HM; Yan B; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
J Natl Compr Canc Netw; 2020 May; 18(5):582-589. PubMed ID: 32380463
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
7. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
8. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Chen YT; Seeruttun SR; Wu XY; Wang ZX
Front Oncol; 2019; 9():1432. PubMed ID: 31921683
[No Abstract] [Full Text] [Related]
9. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML; Dakhil CSR; Stella P; Jin Y; Shames DS; Schleifman E; Fabrizio DA; Phan S; Socinski MA
Nat Med; 2022 May; 28(5):939-945. PubMed ID: 35422531
[TBL] [Abstract][Full Text] [Related]
10. A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.
Lin J; Wang X; Zhang C; Bu S; Zhao C; Wang H
Front Immunol; 2021; 12():606027. PubMed ID: 34248926
[TBL] [Abstract][Full Text] [Related]
11. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial.
Park CK; Jun HR; Oh HJ; Lee JY; Cho HJ; Kim YC; Lee JE; Yoon SH; Choi CM; Lee JC; Lee SY; Lee SY; Chun SM; Oh IJ
Cells; 2023 Apr; 12(9):. PubMed ID: 37174645
[TBL] [Abstract][Full Text] [Related]
13. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
Zhang S; Yang L; Yang Y; Xin Y; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
[TBL] [Abstract][Full Text] [Related]
14. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
[TBL] [Abstract][Full Text] [Related]
15. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR; Paul SM; Kowanetz M; Schleifman E; Zou W; Li Y; Rittmeyer A; Fehrenbacher L; Otto G; Malboeuf C; Lieber DS; Lipson D; Silterra J; Amler L; Riehl T; Cummings CA; Hegde PS; Sandler A; Ballinger M; Fabrizio D; Mok T; Shames DS
Nat Med; 2018 Sep; 24(9):1441-1448. PubMed ID: 30082870
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring
Nie W; Gan L; Wang X; Gu K; Qian FF; Hu MJ; Zhang D; Chen SQ; Lu J; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Li CH; Yang P; Xu MD; Zhang XY; Zhong H; Han BH
Oncoimmunology; 2021 Jan; 10(1):1865670. PubMed ID: 33537171
[TBL] [Abstract][Full Text] [Related]
18. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
19. Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Ma Y; Li Q; Du Y; Cai J; Chen W; Zhao G; Liu X; Li H; Ma L; Huang Y; Zhou Y
Front Oncol; 2021; 11():640761. PubMed ID: 34055609
[TBL] [Abstract][Full Text] [Related]
20. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.
Fan Y; Liu Y; Wang L; Cai Y; Cao W; Sun W; Zou X; Li B; Zhang Z; Cai S; Chuai S; Han Y; Pan X; Huang D
EBioMedicine; 2023 May; 91():104564. PubMed ID: 37094467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
